Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2007 Dec;24(12):629-34.
doi: 10.1007/s10815-007-9178-x. Epub 2007 Dec 11.

Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function

David Barad  1 , Hyama Brill, Norbert Gleicher
Affiliations
Comparative Study

Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function

David Barad et al. J Assist Reprod Genet. 2007 Dec.

Abstract

Objective: We assessed the role of DHEA supplementation on pregnancy rates in women with diminished ovarian function.

Design: This is a case control study of 190 women with diminished ovarian function. The study group includes 89 patients who used supplementation with 75 mg daily of oral, micronized DHEA for up to 4 months prior to entry into in vitro fertilization (IVF). The control group is composed of 101 couples who received infertility treatment, but did not use DHEA. The primary outcome was clinical pregnancy after the patient's initial visit. We developed a Cox proportional hazards model to compare the proportional hazards of pregnancy among women using DHEA with the controls group.

Results: Cumulative clinical pregnancy rates were significantly higher in the study group (25 pregnancies; 28.4% vs. 11 pregnancies; 11.9%; relative hazard of pregnancy in study group (HR 3.8; 95% CI 1.2-11.8; p < 0.05).

Conclusions: DHEA treatment resulted in significantly higher cumulative pregnancy rates. These data support a beneficial effect of DHEA supplementation among women with diminished ovarian function.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cumulative pregnancy rate based on Cox regression of time from initial visit to clinical pregnancy or censor by DHEA use stratified by ovarian reserve and adjusted for ART treatment, race/ethnicity, age and baseline FSH (HR 3.8; 95% CI 1.2–11.8; p < 0.05)
See this image and copyright information in PMC

References

    1. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod. 2000;15(10):2129–32. doi: 10.1093/humrep/15.10.2129. - DOI - PubMed
    1. Barad D, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril. 2005;84(3):756. doi: 10.1016/j.fertnstert.2005.02.049. - DOI - PubMed
    1. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006;21(11):2845–9. doi: 10.1093/humrep/del254. - DOI - PubMed
    1. ASRM/SART-Registry Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril. 2004;81(5):1207–20. doi: 10.1016/j.fertnstert.2004.01.017. - DOI - PubMed
    1. Barad D, Weghofer A, Gleicher N. O-291: evidence for an empiric definition of diminished ovarian reserve (DOR), ovarian resistance to stimulation and diagnosis of premature ovarian aging (POA), based on age-specific baseline FSH levels. Fertil Steril. 2006;86(3, Supplement 1):S125–S6. doi: 10.1016/j.fertnstert.2006.07.331. - DOI

Substances